Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring
Disease area: Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Isabelle Sermet-Gaudelus (Paris, France), Isabelle Sermet-Gaudelus, Harm Tiddens, Anne Malfroot, Harry Heijerman, Eitan Kerem, Lena Hjelte, Yiping Sun, Joseph McIntosh, Jane Davies, Christiane de Boeck. Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: Evaluation of exacerbations and lung function. Eur Respir J 2016; 48: Suppl. 60, 4869

Member's Comments

No comment yet.

Related content which might interest you: Safety, tolerability and efficacy of intravenous aminophylline in adult patients with pulmonary exacerbations of cystic fibrosis Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects Year: 2014 Inhaled corticosteroids and lower lung function decline in young children with cystic fibrosis Source: Eur Respir J 2011; 37: 1091-1095 Year: 2011 Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis Source: Eur Respir J 2002; 20: 122-126 Year: 2002 Inhaled colistin following lung transplantation in colonised cystic fibrosis patients Source: Eur Respir J 2013; 42: 542-544 Year: 2013 The oral AntibioticS approprIateness score (OASIS) – A novel scoring system to assess antibiotic route in pulmonary exacerbations of cystic fibrosis (CF) Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults Year: 2013 Effect of azithromycin on FEV1 and exacerbation frequency in adult non-cystic fibrosis bronchiectasis Source: Eur Respir J 2007; 30: Suppl. 51, 528s Year: 2007 Effects of long-term azithromycin treatment in patients with non-cystic fibrosis stable bronchiectasis Source: Annual Congress 2007 - Infectious lung and pleural diseases Year: 2007 Improvement in pulmonary function after IV antibiotic treatment in cystic fibrosis patients Source: Eur Respir J 2002; 20: Suppl. 38, 342s Year: 2002 Lung clearance index in cystic fibrosis subjects treated for pulmonary exacerbations Source: Eur Respir J 2015; 46: 1055-1064 Year: 2015 Assessing response to treatment of exacerbations of bronchiectasis in adults Source: Eur Respir J 2009; 33: 312-318 Year: 2009 Long-term administration of aerosolised tobramycin in patients with cystic fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 619s Year: 2005 Efficacy and safety of inhaled antibiotics for chronic pseudomonas infection in cystic fibrosis: Network meta-analysis Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring Year: 2016 Side effects of inhaled tobramycin in patients with Cystic Fibrosis Source: Eur Respir J 2002; 20: Suppl. 38, 526s Year: 2002 Early detection of pulmonary exacerbations in children with cystic fibrosis by electronic home monitoring of symptoms and lung function Source: International Congress 2016 – Cystic fibrosis: monitoring and management Year: 2016 Inhalation therapy in cystic fibrosis Source: School Course 2013 - Cystic Fibrosis Year: 2013 Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor: A secondary analysis Source: Annual Congress 2013 –Cystic fibrosis: lung function and change of lung function in infants and children before and after treatment Year: 2013 Variation in lung function as a marker of adherence to oral and inhaled medication in cystic fibrosis Source: Eur Respir J , 49 (3) 1600987; DOI: 10.1183/13993003.00987-2016 Year: 2017 Lung clearance index improves with treatment of an exacerbation in cystic fibrosis Source: Annual Congress 2007 - Cystic fibrosis lung disease: from diagnosis to end-stage Year: 2007